Forte Biosciences Announces Q2 2025 Results and Trials

The latest update is out from Forte Biosciences ( (FBRX) ).

On August 14, 2025, Forte Biosciences announced its second quarter 2025 financial results and provided a business update, highlighting the initiation of three clinical trials for its product FB102. The company expects data readouts in 2026 for phase 2 in celiac disease and phase 1b in both vitiligo and alopecia areata, which could significantly impact its market positioning by addressing unmet medical needs. Additionally, Forte closed a public offering in June 2025, raising $69.9 million, which strengthens its financial position to advance its clinical programs.

The most recent analyst rating on (FBRX) stock is a Buy with a $68.75 price target. To see the full list of analyst forecasts on Forte Biosciences stock, see the FBRX Stock Forecast page.

Spark’s Take on FBRX Stock

According to Spark, TipRanks’ AI Analyst, FBRX is a Underperform.

Forte Biosciences faces significant challenges with no revenue and increasing operational losses, leading to a weak financial performance. Technical analysis indicates a mixed outlook with bearish long-term trends. The negative P/E ratio and lack of dividend yield highlight valuation concerns. Without positive developments in these areas, the stock remains highly speculative and risky.

To see Spark’s full report on FBRX stock, click here.

More about Forte Biosciences

Forte Biosciences, Inc. is a clinical-stage biopharmaceutical company focused on developing treatments for autoimmune and autoimmune-related diseases. The company is working on FB102, a product aimed at addressing conditions such as celiac disease, vitiligo, and alopecia areata, which represent significant market opportunities.

Average Trading Volume: 102,484

Technical Sentiment Signal: Sell

Current Market Cap: $131.4M

Find detailed analytics on FBRX stock on TipRanks’ Stock Analysis page.